Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers.

Pharmacogenomics - 1 May 2016

Tkáč Ivan, Gotthardová Ivana

Abstract excerpt

Incretin effect enhancers are drugs used in the treatment of Type 2 diabetes and include GLP-1 receptor agonists and dipeptidyl peptidase-4 inhibitors (gliptins). Variants in several genes were shown to be involved in the physiology of incretin secretion. Only two gene variants have evidence also from pharmacogenetic studies. TCF7L2 rs7903146 C>T and CTRB1/2 rs7202877 T>G minor allele carriers were both...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Chymotrypsin

Share to Diabetes Mellitus, Type 2

Share to Hypoglycemic Agents

Share to KCNQ1 Potassium Channel

Share to Pharmacogenomic Testing

Share to Pharmacogenomic Variants

Share to Polymorphism, Single Nucleotide

Share to Transcription Factor 7-Like 2 Protein

Source

Identifiers

PMID: 27166975
DOI: 10.2217/pgs-2016-0011

Genes

CTRB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Pharmacogenetic aspects of the treatment of Type 2 diabetes with the incretin effect enhancers.PMID 27166975Read ↗

A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes.Semantic proximity Read ↗

Pharmacogenomics of GLP-1 Receptor Agonists: A genome wide analysis of observational data and large randomized controlled trialsSemantic proximity Read ↗

Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study.Semantic proximity Read ↗

Association between variants in TCF7L2, CTRB1/2, and GLP-1R genes and response to therapy with glucagon-like peptide-1 receptor agonists.Semantic proximity Read ↗

A missense variant in GLP1R gene is associated with the glycaemic response to treatment with gliptins.Semantic proximity Read ↗

Genetic variants associated with glycemic response to treatment with dipeptidylpeptidase 4 inhibitors.Semantic proximity Read ↗

Tailoring Type II Diabetes Treatment: Investigating the Effect of 5-HTT Polymorphisms on HbA1c Levels after Metformin Initiation.Semantic proximity Read ↗

Highlights from the latest articles in diabetes pharmacogenomics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.